Comparative Pharmacology
Head-to-head clinical analysis: CORZIDE versus LOTREL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORZIDE versus LOTREL.
CORZIDE vs LOTREL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of a beta-adrenergic receptor antagonist (nadolol) and a thiazide diuretic (bendroflumethiazide). Nadolol non-selectively blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Bendroflumethiazide inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water.
Lotrel is a combination of amlodipine (a calcium channel blocker) and benazepril (an ACE inhibitor). Amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle cells, causing vasodilation and reduced blood pressure. Benazepril inhibits angiotensin-converting enzyme, reducing angiotensin II formation, leading to vasodilation and decreased aldosterone secretion.
Oral: 1 tablet daily containing nadolol 40 mg and bendroflumethiazide 5 mg. May increase to 2 tablets daily if needed.
Oral: 1 capsule (amlodipine 2.5 mg/benazepril 10 mg) once daily, titrate to maximum 10 mg/40 mg once daily.
None Documented
None Documented
Nadolol: 14-24 hours (prolonged in renal impairment up to 45 hours); bendroflumethiazide: 8-9 hours (may be prolonged in renal dysfunction).
Amlodipine: 30-50 hours (terminal); steady state in 7-10 days. Benazeprilat: 10-11 hours (terminal); effective half-life 22-24 hours with once-daily dosing.
Nadolol: ~73% excreted unchanged in urine via glomerular filtration; bendroflumethiazide: ~30% excreted unchanged in urine, remainder as metabolites via renal and biliary routes.
Amlodipine: 60% renal, 20-25% fecal. Benazeprilat: 85% renal (as benazeprilat and conjugated metabolites), 15% biliary/fecal.
Category C
Category C
Antihypertensive combination
Antihypertensive combination